Breast cancer — what does prevention involve, and when should you see a breast surgeon?

Medical author: Iwona Chruścicka, MD, PhD, general and oncological surgeon specialising in the diagnosis and treatment of breast diseases — subject to authorisation before publication · Editorial preparation: Wyspa Medycyny Przyjaznej Editorial Team · Medical review: Iwona Chruścicka, MD, PhD — to be confirmed before publication · Publication: to be completed · Updated: 10 July 2026

This article is educational and does not replace a medical consultation. A new breast lump, nipple or skin retraction, bloody nipple discharge, ulceration, an orange-peel appearance of the skin, enlarged axillary lymph nodes, or a concerning ultrasound or mammography result requires medical assessment.

Key information at a glance

• A breast lump does not always mean cancer. It may be a cyst, fibroadenoma, inflammatory lesion, post-traumatic change, benign proliferation or cancer.
• Every new, hard, growing, persistent or concerning breast lesion requires investigation, regardless of the patient’s age.
• In Poland, the National Health Fund breast cancer screening programme includes mammography for women aged 45–74, usually every 24 months if programme criteria are met.
• Breast ultrasound and mammography are not competing tests — they are selected according to age, breast structure, symptoms and previous test results.
• BI-RADS is a radiological scale describing the level of suspicion and suggesting further management. It is not itself a cancer diagnosis.
• BI-RADS 1–2 usually indicates a normal or benign result, BI-RADS 3 requires short-term follow-up, and BI-RADS 4–5 usually means a biopsy is needed.
• Fine-needle aspiration is most often used for cytological assessment or cystic lesions. Core needle biopsy obtains tissue for histopathology and is the primary method when breast cancer is suspected.
• Breast cancer is diagnosed on the basis of histopathological examination, not solely by palpation, ultrasound, mammography or BI-RADS.
• A breast surgeon helps organise the diagnostic process, interpret results, qualify the patient for biopsy, discuss histopathology and plan further treatment.

Learn more about the specialist

Iwona Chruścicka, MD, PhD, is a general and oncological surgeon with many years of experience in diagnosing and treating breast diseases. At Wyspa Medycyny Przyjaznej, she helps patients interpret ultrasound and mammography findings, qualify for biopsy, diagnose breast lumps and plan further surgical or hospital treatment.

Meet Iwona Chruścicka, MD, PhD

Does this topic make sense for SEO, AI and Google Search?

Yes. Patients often search directly for questions such as: “does a breast lump mean cancer?”, “what does BI-RADS 3 mean?”, “is BI-RADS 4 cancer?”, “does a core needle breast biopsy hurt?”, “fine-needle versus core needle biopsy”, “when should I see a breast surgeon?”, “breast cancer prevention after 40”, “mammography or breast ultrasound?”, and “what does a breast histopathology result mean?”. This article addresses these intentions but does not replace service pages about breast lumps, biopsy or surgical consultations.

For oncology topics, E-E-A-T is especially important: a medical author, update date, medical review, cautious language, red-flag symptoms, sources and a clear explanation that a cancer diagnosis requires tissue examination. The text should neither frighten patients about every lesion nor reassure them without diagnostics.

Breast cancer prevention — what does it really mean?

Breast cancer prevention is not a single test but several complementary actions. The most important are participation in screening, prompt response to new symptoms, familiarity with one’s own breasts, assessment of family risk and regular medical consultation when an imaging result is abnormal or unclear.

In Poland, women aged 45–74 can participate in the National Health Fund breast cancer screening programme. Mammography is the screening test used in this programme and is intended to detect changes before they become palpable. However, women outside this age range or women with symptoms should not wait for screening. A breast symptom requires investigation regardless of age or the screening calendar.

Prevention does not mean “looking for cancer every day” and living in fear. It means reasonable vigilance: knowing what is normal for you, noticing a change and not postponing diagnostics.

Mammography, breast ultrasound or MRI — which test is “best”?

There is no single best test for every patient and every situation. Mammography is the main screening test in selected age groups. Breast ultrasound is often used in younger women, in dense breasts, for a palpable lump, cysts, lesion follow-up and as a supplement to mammography. Breast MRI is used in selected situations, for example in high-risk patients or advanced diagnostics, but it does not routinely replace all other tests.

The key is to match the examination to the clinical question. An asymptomatic patient in a screening programme is assessed differently from a young woman with a palpable lump, a patient after breast cancer treatment or a person with a significant family history or genetic mutation.

Does a breast lump always mean cancer?

No. This is one of the most common and stressful questions. A breast lump may be benign, a fluid-filled cyst, fibroadenoma, inflammatory, post-traumatic, fatty, hormone-dependent or malignant. Many breast lesions are not cancer, but this cannot be determined reliably by touch alone.

Particularly concerning features include a new, hard, irregular, growing or fixed lesion, skin or nipple retraction, bloody discharge, enlarged axillary nodes or a change in breast shape. Lack of pain is not reassuring because many cancers may be painless. Conversely, pain does not automatically mean cancer, as it may accompany cysts, inflammation and hormonal changes.

The correct answer is therefore: a breast lump is not the same as cancer, but it requires investigation. The aim is to distinguish benign lesions from those requiring biopsy or treatment.

Which breast symptoms should prompt a consultation?

You should see a doctor if you notice:

• a new lump, thickening or asymmetry in the breast,
• a lump in the armpit or an enlarged lymph node,
• retraction of the skin or nipple,
• a change in the shape or size of one breast,
• bloody, unilateral or spontaneous nipple discharge,
• redness, swelling, warmth or tenderness persisting despite treatment,
• skin resembling orange peel,
• ulceration, crusting, scaling or a non-healing nipple lesion,
• focal pain that does not resolve or worsens,
• an abnormal breast ultrasound, mammography or MRI result.

When symptoms are present, do not wait for the next routine mammogram in a screening programme. A clinical symptom requires diagnostic assessment, not screening alone.

When should a patient see a breast surgeon?

A patient usually sees a breast surgeon when there is a palpable lump, a concerning ultrasound or mammography result, a BI-RADS category requiring follow-up or biopsy, a recommendation for core needle biopsy, a histopathology result that needs discussion, or a need to qualify for lesion removal.

The role of a breast surgeon is not limited to operating. Often the most important task is to organise the diagnostic pathway: review imaging, take a history, examine the breasts and lymph nodes, and decide whether ultrasound, mammography, biopsy, follow-up, histopathology or referral to a breast cancer centre is needed.

A breast surgeon also helps the patient understand whether a lesion is benign or suspicious and whether it requires biopsy, removal, observation or further oncological treatment.

BI-RADS — what does this scale mean in ultrasound or mammography?

BI-RADS is a standardised system for reporting breast imaging. Radiologists use it to describe how benign, indeterminate or suspicious a finding appears and to recommend further management. Importantly, BI-RADS is not a final cancer diagnosis. It is an imaging category that helps determine whether routine screening, short-term follow-up, additional imaging or biopsy is needed.

A common mistake is to panic after seeing “BI-RADS 3” or to ignore a palpable lump after seeing “BI-RADS 2”. Both situations require calm interpretation. Imaging results must always be considered together with the clinical examination and symptoms.

BI-RADS 3, 4 and 5 — what do patients search for most often?

Patients most often search online for answers to: “is BI-RADS 3 cancer?”, “is BI-RADS 4 always cancer?” and “what happens after BI-RADS 5?”. These categories should be clarified.

• BI-RADS 3 usually means a probably benign lesion that requires follow-up. It is not a cancer diagnosis, but it should not be ignored.
• BI-RADS 4 means a suspicious lesion. Not every BI-RADS 4 lesion is cancer, but this category usually requires biopsy to obtain a tissue diagnosis.
• BI-RADS 5 means an image highly suggestive of cancer. However, the final diagnosis still requires biopsy and histopathology.

Patients should not interpret BI-RADS independently of the full report. The lesion type, size, shape, borders, vascularity, changes over time, comparison with previous results and clinical symptoms all matter.

Breast biopsy — why is it performed?

A breast biopsy involves collecting cells or tissue fragments from a lesion for microscopic examination. It is a key step when imaging or clinical assessment cannot safely classify the lesion as benign. The purpose of biopsy is not immediate treatment, but diagnosis.

A biopsy may be recommended for a suspicious lesion on ultrasound, mammography or MRI, a palpable lump, concerning microcalcifications, nipple changes, an unclear imaging result or a BI-RADS category requiring tissue verification.

Important: having a biopsy does not mean that the patient has cancer. It means that the doctor needs tissue to establish a diagnosis. Many biopsies confirm benign findings, but without tissue examination this cannot always be stated responsibly.

Fine-needle aspiration — when can it be used?

Fine-needle aspiration, or FNA, involves collecting cells or fluid from a lesion with a thin needle. The material is assessed cytologically, at the cellular level. It may be helpful for cystic lesions, aspiration of cyst fluid or selected situations where the doctor wants to distinguish a fluid-filled lesion from a solid one quickly.

A limitation of fine-needle aspiration is that it usually does not provide a full tissue fragment showing the architecture of the lesion. When breast cancer is suspected, core needle biopsy is often required because it allows assessment of tissue structure, histological type and — if sufficient tissue is obtained — features important for treatment planning.

The question is therefore not “which biopsy is always better?” but “which biopsy answers the diagnostic question in my case?”. The doctor decides based on the lesion’s appearance, location, BI-RADS category, visibility on ultrasound or mammography and the purpose of the test.

Core needle biopsy — why is it so important when breast cancer is suspected?

Core needle biopsy, often abbreviated as CNB, involves collecting tissue fragments from a lesion. It is usually performed under ultrasound, stereotactic mammography or MRI guidance, depending on which modality best shows the lesion.

Its advantage is that the pathologist receives a tissue fragment rather than individual cells. This allows assessment of whether the lesion is benign or malignant, the histological cancer type and, when cancer is diagnosed and the sample is adequate, parameters important for treatment such as ER/PgR hormone receptors, HER2, Ki-67 and tumour grade.

In practice, the core biopsy result may determine whether the patient needs observation, surgical removal, additional diagnostics, treatment at an oncology centre or discussion by a multidisciplinary team.

Can a biopsy “spread cancer”?

This is a common concern. Breast cancer diagnostics worldwide rely on biopsy because treatment cannot be safely planned without a tissue diagnosis. Fear of biopsy should not delay the investigation of a suspicious lesion.

To be clear: biopsy does not “provoke cancer”; it is a way to find out what the lesion is. Avoiding biopsy in a suspicious lesion may delay diagnosis and treatment. Patients with concerns should ask why biopsy is recommended, which method will be used, what imaging guidance is planned, what complications are possible and when the result will be available.

Histopathological examination — what does the result actually tell us?

Histopathology is the microscopic assessment of collected tissue by a pathologist. It answers the key question of whether cancer cells are present and whether the lesion is benign, pre-invasive, malignant or requires further diagnostics.

In breast cancer, the result may include:

• the histological tumour type,
• whether the cancer is invasive or in situ,
• the histological grade,
• oestrogen and progesterone receptors,
• HER2 status,
• the Ki-67 proliferation index,
• information about surgical margins if tissue after excision is examined,
• other features relevant to further treatment.

The patient should not be left alone with a histopathology report. It must be discussed with a doctor because it determines the next steps: observation, lesion removal, surgery, oncological treatment, hormone therapy, radiotherapy, chemotherapy or targeted therapy, depending on the diagnosis.

When does a breast lump need to be removed surgically?

Not every breast lump requires excision. Some benign lesions can be observed if the clinical examination, ultrasound or mammography and any biopsy result are consistent. However, some lesions require removal even when they are not cancer, for example if they grow, cause symptoms, create diagnostic uncertainty, have an inconclusive biopsy result or belong to a higher-risk category.

Surgical removal may be considered in cases of:

• a suspicious or indeterminate lesion after diagnostics,
• a lesion that grows on consecutive examinations,
• discordance between the clinical examination, imaging and biopsy result,
• a benign lump causing pain, pressure or deformity,
• a lesion requiring complete histopathological assessment after removal,
• confirmed breast cancer when breast-conserving surgery or mastectomy is part of treatment.

The decision should take into account not only the result, but also the patient’s age, family history, genetic risk, lesion location and size, relationship to the nipple and skin, the possibility of preserving breast appearance and the patient’s preferences.

What happens if the biopsy confirms breast cancer?

Confirmation of breast cancer is emotionally difficult, but it does not mean treatment begins in chaos. The next step is to organise the information: cancer type, whether it is invasive, receptor status, lesion size, whether lymph nodes are suspicious and whether additional imaging is needed.

Breast cancer treatment should be planned individually, preferably at a centre or by a team specialising in breast cancer. Depending on the situation, the patient may need breast-conserving surgery, mastectomy, sentinel lymph node biopsy, chemotherapy, hormone therapy, radiotherapy, targeted therapy or preoperative systemic treatment.

The breast surgeon’s role is not limited to discussing surgery. It is important to explain the sequence of treatment, the meaning of the histopathology result, possible scenarios and why one patient undergoes surgery first while another receives systemic treatment before surgery.

Common myths about breast cancer and breast lumps

• “If the lump hurts, it is not cancer.” False. Pain is more common in benign conditions, but it does not rule out cancer.
• “If the mammogram was normal, a new lump can be ignored.” False. A new symptom requires assessment even if the previous test was normal.
• “Ultrasound is always enough.” False. Some patients need mammography, biopsy or another examination.
• “BI-RADS 4 definitely means cancer.” No. It means a suspicious lesion that usually requires biopsy.
• “Biopsy spreads cancer.” This concern should be discussed with a doctor, but biopsy is a standard part of diagnosing suspected breast cancer.
• “Young women do not get breast cancer.” Risk increases with age, but symptoms in younger women also require investigation.
• “No one in my family had it, so it cannot affect me.” Family history matters, but most patients with breast cancer do not necessarily have multiple cases in the family.

When should diagnostics not be delayed?

Prompt consultation is particularly important for:

• a new, hard or growing breast lump,
• skin or nipple retraction,
• bloody, unilateral or spontaneous nipple discharge,
• redness and swelling of the breast that does not improve,
• an orange-peel appearance,
• ulceration of the breast skin or nipple,
• an enlarged axillary lymph node,
• a BI-RADS 4 or 5 result,
• BI-RADS 0 when urgent additional diagnostics have been recommended,
• a discrepancy where the patient feels a lump but the test result is unclear or does not explain the symptom.

In such situations, do not reassure yourself and postpone consultation “until after the holidays” or “until after your period” if the change persists or causes concern.

Can you feel a breast lump or have a concerning ultrasound or mammography result?

Do not interpret the result alone or assume the worst. A breast surgeon consultation can determine whether observation, biopsy, histopathological examination or further treatment is needed.

Breast surgery at Wyspa Medycyny Przyjaznej in Gdańsk

At Wyspa Medycyny Przyjaznej, Iwona Chruścicka, MD, PhD, helps women and men with breast disease diagnostics, interpretation of imaging, qualification for biopsy, discussion of histopathology results and planning further treatment. Breast surgery is a particular area of her work, covering both benign lesions and conditions requiring oncological diagnostics.

Depending on the situation, a patient may need a surgical consultation, ultrasound or interpretation of a result, core needle biopsy, surgical removal, histopathology or referral for treatment at a specialist centre. The current scope of services, doctor availability, prices and appointment preparation should be confirmed with reception.

Learn more about Dr Iwona Chruścicka Breast lump Surgery

What should you ask a breast surgeon during the appointment?

• Does my lump look benign, cystic, inflammatory or suspicious?
• Does the ultrasound or mammography result match what I can feel in my breast?
• What does my BI-RADS category mean?
• Do I need follow-up, additional imaging or biopsy?
• Which biopsy is appropriate in my case: fine-needle, core needle, vacuum-assisted or stereotactic?
• Will the biopsy be performed under ultrasound, mammography or MRI guidance?
• When will the result be available and who will discuss it with me?
• What exactly does the histopathology result mean?
• Does the lesion need to be removed surgically?
• Do I need a consultation at a breast cancer treatment centre?
• Does my family history require genetic counselling?
• When should I seek urgent help?

FAQ — breast cancer, BI-RADS, biopsy and breast surgeon

Does a breast lump always mean cancer?

No. A breast lump may be a cyst, fibroadenoma, inflammatory or hormonal change, benign proliferation or cancer. Every new or concerning lesion requires investigation.

What does BI-RADS mean?

BI-RADS is a scale used in breast imaging reports. It helps indicate whether a result is normal, benign, requires follow-up, further tests or biopsy. It is not a final cancer diagnosis.

Does BI-RADS 4 mean cancer?

Not always. BI-RADS 4 means a suspicious lesion that usually requires biopsy. Some BI-RADS 4 lesions are benign, but this cannot be established reliably without tissue examination.

Is BI-RADS 5 definitely cancer?

BI-RADS 5 means an image highly suggestive of cancer, but the final diagnosis requires biopsy and histopathology.

What is the difference between fine-needle and core needle biopsy?

Fine-needle aspiration collects cells or fluid for cytological assessment. Core needle biopsy obtains tissue fragments for histopathology and is the primary method when breast cancer is suspected.

Does a breast biopsy hurt?

A biopsy is usually performed under local anaesthesia. The patient may feel a needle prick, pressure, fullness or discomfort. Bruising, tenderness or mild swelling may occur afterwards.

Can a biopsy spread cancer?

Biopsy is a standard part of diagnosing suspected breast cancer. Its purpose is to obtain a tissue diagnosis, without which treatment cannot be responsibly planned.

When is histopathological examination needed?

Histopathology is needed when tissue collected during biopsy or surgery must be assessed. It confirms whether a lesion is benign, precancerous, cancerous or requires further treatment.

When should I see a breast surgeon?

A breast surgeon consultation is recommended for a palpable lump, a concerning ultrasound or mammography result, BI-RADS 4–5, a biopsy recommendation, an unclear histopathology result or a need for lesion removal.

Is mammography enough for breast cancer prevention?

Mammography is the main screening test in selected age groups, but it does not replace consultation when symptoms are present. A lump, bloody discharge, skin retraction or another concerning symptom requires diagnostics regardless of the screening programme.

Who provides breast disease consultations at WMP?

On the WMP website, Iwona Chruścicka, MD, PhD, is described as a general and oncological surgeon with experience in diagnosing and treating breast diseases. She helps interpret tests, qualify patients for biopsy and plan further treatment.

Sources for medical and editorial verification

• Wyspa Medycyny Przyjaznej, Iwona Chruścicka, MD, PhD: https://www.wyspamedycynyprzyjaznej.pl/en/dr-iwona-chruscicka
• Wyspa Medycyny Przyjaznej, breast lump — diagnostics, biopsy and treatment: https://www.wyspamedycynyprzyjaznej.pl/en/guz-piersi
• Pacjent.gov.pl, breast cancer prevention: https://pacjent.gov.pl/program-profilaktyczny/profilaktyka-raka-piersi
• National Health Fund, mammography and cytology — changes to prevention programmes: https://www.nfz.gov.pl/aktualnosci/aktualnosci-centrali/mammografia-i-cytologia-wazne-zmiany-w-programach-profilaktycznych-na-nfz,8497.html
• American Cancer Society, breast cancer screening guidelines: https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
• National Cancer Institute, benign and precancerous breast lumps and conditions: https://www.cancer.gov/types/breast/causes-risk-factors/benign-breast-lumps
• National Cancer Institute, understanding breast changes: https://www.cancer.gov/types/breast/breast-changes
• Mayo Clinic, breast biopsy: https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812
• Łukasiewicz E. et al., Fine-needle versus core-needle biopsy — which one to choose in preoperative assessment of focal lesions in the breasts?, PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC5769667/
• StatPearls / NCBI Bookshelf, Breast Imaging Reporting and Data System: https://www.ncbi.nlm.nih.gov/books/NBK459169/
• City of Hope, BI-RADS categories 1–6 and what they mean: https://www.cityofhope.org/clinical-program/breast-cancer/screening/mammogram/results-bi-rads
• NCCN / JNCCN, Breast Cancer Screening and Diagnosis: https://jnccn.org/view/journals/jnccn/16/11/article-p1362.xml
• Cancer Australia, use of fine needle aspiration and core biopsy in breast assessment: https://www.canceraustralia.gov.au/resources/position-statements/position-statement-use-fine-needle-aspiration-and-core-biopsy-breast-breastscreen-australia-program/guidance
• Google Search Central, Creating helpful, reliable, people-first content: https://developers.google.com/search/docs/fundamentals/creating-helpful-content
• Google Search Central, Article structured data: https://developers.google.com/search/docs/appearance/structured-data/article
• Google Search Quality Rater Guidelines: https://guidelines.raterhub.com/searchqualityevaluatorguidelines.pdf